You just read:

Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch

News provided by

Enanta Pharmaceuticals

Sep 26, 2011, 09:02 ET